Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Highlights
- ➤SER-252 advanced to Cohort 2 after independent Safety Monitoring Committee review
- ➤Cohort 2 dosing underway; topline single-ascending-dose data expected first half of 2027
- ➤Third-quarter net loss $7.9 million, or $(0.31) per share
- ➤Third-quarter operating expenses $8.0 million, up from $6.4 million year over year
- ➤Cash and equivalents $19.4 million as of September 30, 2026
Expert Statements
Steve Ledger, Chief Executive Officer of Serina Therapeutics
“We are excited about the achievement of important clinical milestones for SER-252 in Parkinson's disease, advancing from the initial evaluation of our lowest-dose cohort into the next stage of dose escalation”
Steve Ledger, Chief Executive Officer of Serina Therapeutics
“Importantly, the blinded pharmacokinetic observations from Cohort 1 showed the sustained drug exposure SER-252 was designed to achieve, and the independent Safety Monitoring Committee recommended proceeding with continued development.”
Steve Ledger, Chief Executive Officer of Serina Therapeutics
“Dosing in Cohort 2 is currently underway and focuses on demonstrating SER-252's potential as a differentiated treatment option for patients with advanced Parkinson's disease to improve the significant challenge of consistent symptom control.”
– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2 – Dosing initiated in Cohort 2 of the registrational study; topline single-ascending-dose data expected in the first half of 2027 –
HUNTSVILLE, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform(™) drug optimization technology, today reported its financial results for the third quarter ended September 30, 2026, along with key business updates.
Get started
Create a free account to read the full story.